1. Home
  2. PGY vs DNTH Comparison

PGY vs DNTH Comparison

Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$21.85

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$41.83

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
DNTH
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGY
DNTH
Price
$21.85
$41.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$39.86
$68.00
AVG Volume (30 Days)
2.5M
678.9K
Earning Date
02-12-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,245,946,000.00
$3,078,000.00
Revenue This Year
$28.75
N/A
Revenue Next Year
$17.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
28.33
N/A
52 Week Low
$8.27
$13.37
52 Week High
$44.99
$45.46

Technical Indicators

Market Signals
Indicator
PGY
DNTH
Relative Strength Index (RSI) 40.60 51.40
Support Level $22.72 $42.02
Resistance Level $24.06 $44.00
Average True Range (ATR) 1.31 1.80
MACD 0.01 -0.28
Stochastic Oscillator 16.63 42.45

Price Performance

Historical Comparison
PGY
DNTH

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: